Next Article in Journal
Dimerized Domain V of Beta2-Glycoprotein I Is Sufficient to Upregulate Procoagulant Activity in PMA-Treated U937 Monocytes and Require Intact Residues in Two Phospholipid-Binding Loops
Previous Article in Journal
Collagen Autoantibodies and Their Relationship to CCP Antibodies and Rheumatoid Factor in the Progression of Early Rheumatoid Arthritis
Previous Article in Special Issue
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
Article Menu

Export Article

Open AccessArticle
Antibodies 2017, 6(2), 7; doi:10.3390/antib6020007

Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function

1
Zymeworks Inc., 540-1385 West 8th Ave, Vancouver, BC V6H 3V9, Canada
2
Human Health Therapeutics, National Research Council Canada, 6100 Royalmount Ave, Montreal, QC H4P 2R2, Canada
*
Authors to whom correspondence should be addressed.
Academic Editors: Christian Klein and Dimiter S. Dimitrov
Received: 8 November 2016 / Revised: 10 March 2017 / Accepted: 25 April 2017 / Published: 16 May 2017
(This article belongs to the Special Issue Advances in Bispecific Antibodies)
View Full-Text   |   Download PDF [2855 KB, uploaded 16 May 2017]   |  

Abstract

Asymmetric bispecific antibodies are a rapidly expanding therapeutic antibody class, designed to recognize two different target epitopes concurrently to achieve novel functions not available with normal antibodies. Many therapeutic designs require antibodies with reduced or silenced effector function. Although many solutions have been described in the literature to knockout effector function, to date all of them have involved the use of a specific antibody subtype (e.g., IgG2 or IgG4), or symmetric mutations in the lower hinge or CH2 domain of traditional homodimeric monospecific antibodies. In the context of a heterodimeric Fc, we describe novel asymmetric Fc mutations with reduced or silenced effector function in this article. These heteromultimeric designs contain asymmetric charged mutations in the lower hinge and the CH2 domain of the Fc. Surface plasmon resonance showed that the designed mutations display much reduced binding to all of the Fc gamma receptors and C1q. Ex vivo ADCC and CDC assays showed a consistent reduction in activity. Differential scanning calorimetry showed increased thermal stability for some of the designs. Finally, the asymmetric nature of the introduced charged mutations allowed for separation of homodimeric impurities by ion exchange chromatography, providing, as an added benefit, a purification strategy for the production of bispecific antibodies with reduced or silenced effector function. View Full-Text
Keywords: Fc engineering; asymmetric bispecific antibody; ion exchange chromatography; knock-out effector function Fc engineering; asymmetric bispecific antibody; ion exchange chromatography; knock-out effector function
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Escobar-Cabrera, E.; Lario, P.; Baardsnes, J.; Schrag, J.; Durocher, Y.; Dixit, S. Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function. Antibodies 2017, 6, 7.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top